ArticleAlzheimer's research & therapy2026
A novel PGK1 activator improves Alzheimer's disease by regulating glycolysis.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the pathological accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles. Decreased glucose metabolism and ATP levels are well-established early biomarkers of AD. Recent studies indicate that the activation of phosphoglycerate kinase 1 (PGK1), a critical enzyme in the glycolytic pathway, promotes glucose metabolism and ATP production, thus offering potential therapeutic benefits for AD. However, two significant gaps persist: The expression pattern of PGK1 across different brain cell types remains unclear, and the structural diversity of known PGK1 activators is limited, restricting comprehensive investigation. In this study, we show that PGK1 exhibits high expression in neurons in the brain, and that reduced PGK1 expression is evident in both AβO-induced SH-SY5Y cells and 3×Tg-AD mice. PGK1 overexpression mitigates AβO-induced damage by enhancing glycolysis. Through surface plasmon resonance and molecular dynamics simulations, we identify compound L03 (Specs ID: AT-051/43421517) as a novel PGK1 activator. Pretreatment with compound L03 protects against AβO-induced glycolytic dysfunction in SH-SY5Y cells. Furthermore, administration of compound L03 ameliorates cognitive deficits, Aβ deposition, and Tau hyperphosphorylation in 3×Tg-AD mice. Our findings highlight PGK1 as a crucial regulator of neuronal bioenergetics in AD and position compound L03 as a promising PGK1 activator for restoring glycolytic function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.